AN2 Therapeutics (ANTX) Assets Average (2022 - 2026)

AN2 Therapeutics (ANTX) has 5 years of Assets Average data on file, last reported at $74.7 million in Q1 2026.

• Assets Average for Q1 2026 came in at $74.7 million, down 13.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $74.7 million (down 13.83% YoY), and the FY2025 annual result was $77.0 million, down 33.27% from the prior year.
• Assets Average climbed to $74.7 million in Q1 2026 per ANTX's latest filing, from $64.6 million in the prior quarter.
• Over five years, Assets Average peaked at $146.3 million in Q4 2023 and troughed at $64.6 million in Q4 2025.
• A 5-year average of $101.1 million and a median of $96.8 million in 2023 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2024: Assets Average surged 37.63% in 2023, then slumped 35.13% in 2024.
• A 5-year view of Assets Average shows it stood at $106.3 million in 2022, then jumped by 37.63% to $146.3 million in 2023, then tumbled by 35.13% to $94.9 million in 2024, then plunged by 31.93% to $64.6 million in 2025, then advanced by 15.68% to $74.7 million in 2026.
• Business Quant data shows ANTX's Assets Average at $74.7 million in Q1 2026, $64.6 million in Q4 2025, and $71.5 million in Q3 2025.